Risk of Malignancy, Major Adverse Cardiovascular Events, and Liver Injury in Patients with Ulcerative Colitis Treated with Mirikizumab versus Other Biologics: A Secondary Database Study in Japan

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Safety study (incl. comparative)
• Data collection methods:
  Secondary use of data

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  MIRIKIZUMAB
• Anatomical Therapeutic Chemical (ATC) code:
  (L04AC24) mirikizumab

  mirikizumab

Population studied

• Short description of the study population:
  Patients with Ulcerative Colitis